Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An affinity-enhanced, broadly neutralizing heavy chain–only antibody protects against SARS-CoV-2 infection in animal models
Bert Schepens, Loes van Schie, Wim Nerinckx, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 621
Open Access | Times Cited: 55

Showing 26-50 of 55 citing articles:

A nanobody recognizes a unique conserved epitope and potently neutralizes SARS-CoV-2 omicron variants
Naphak Modhiran, Simon Lauer, Alberto A. Amarilla, et al.
iScience (2023) Vol. 26, Iss. 7, pp. 107085-107085
Open Access | Times Cited: 8
Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants
Qi Li, Fiachra Humphries, Roxie C. Girardin, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 11
Broadly Reactive Nanobody Targeting the H3 Hemagglutinin of the Influenza A Virus
Dmitry V. Shcheblyakov, Daria V. Voronina, I. A. FAVORSKAYA, et al.
Acta Naturae (2024) Vol. 16, Iss. 1, pp. 101-110
Open Access | Times Cited: 2
Structure defining of ultrapotent neutralizing nanobodies against MERS-CoV with novel epitopes on receptor binding domain
Sen Ma, Doudou Zhang, Qiwei Wang, et al.
PLoS Pathogens (2024) Vol. 20, Iss. 8, pp. e1012438-e1012438
Open Access | Times Cited: 2
Unraveling the structural and functional dimensions of SARS-CoV2 proteins in the context of COVID-19 pathogenesis and therapeutics
Aniruddh Jhanwar, Dipika Sharma, Uddipan Das
International Journal of Biological Macromolecules (2024) Vol. 278, pp. 134850-134850
Closed Access | Times Cited: 2
Applications of nanobodies in the prevention, detection, and treatment of the evolving SARS-CoV-2
Wenyi Wang, Yue Hu, Bohan Li, et al.
Biochemical Pharmacology (2022) Vol. 208, pp. 115401-115401
Open Access | Times Cited: 10
The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibition
Shuyuan Qiao, Shuyuan Zhang, Jiwan Ge, et al.
FEBS Open Bio (2022) Vol. 12, Iss. 9, pp. 1602-1622
Open Access | Times Cited: 9
Cross-Reactive Fc-Fused Single-Domain Antibodies to Hemagglutinin Stem Region Protect Mice from Group 1 Influenza a Virus Infection
Daria V. Voronina, Dmitry V. Shcheblyakov, I. A. FAVORSKAYA, et al.
Viruses (2022) Vol. 14, Iss. 11, pp. 2485-2485
Open Access | Times Cited: 9
High-throughput ML-guided design of diverse single-domain antibodies against SARS-CoV-2
Christof Angermueller, Zelda Mariet, Benjamin W. Jester, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 5
SARS-CoV-2 infection causes prolonged cardiomyocyte swelling and inhibition of HIF1α translocation in an animal model COVID-19
Margo Daems, Laurens Liesenborghs, Robbert Boudewijns, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 8
Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike
Sieglinde De, Inge Van Molle, Loes van Schie, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 4
A neutralizing single-domain antibody that targets the trimer interface of the human metapneumovirus fusion protein
Marlies Ballegeer, Revina C. van Scherpenzeel, Teresa Delgado, et al.
mBio (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Structural basis for potent neutralization of human respirovirus type 3 by protective single-domain camelid antibodies
Nicole V. Johnson, Revina C. van Scherpenzeel, Mark J. G. Bakkers, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
In vitro high-content tissue models to address precision medicine challenges
Samson Afewerki, Thiago Domingues Stocco, André D. R. Silva, et al.
Molecular Aspects of Medicine (2022) Vol. 91, pp. 101108-101108
Open Access | Times Cited: 6
Nanobodies against SARS-CoV-2 reduced virus load in the brain of challenged mice and neutralized Wuhan, Delta and Omicron Variants
María F. Pavan, Marina Bok, Rafael Betanzos San Juan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Nanobodies in the limelight: Multifunctional tools in the fight against viruses
Ainhoa Moliner Morro, Gerald M. McInerney, Leo Hanke
Journal of General Virology (2022) Vol. 103, Iss. 5
Closed Access | Times Cited: 4
Therapeutic Phage Display-Derived Single-Domain Antibodies for Pandemic Preparedness
Janet M. Daly, Theam Soon Lim, Kevin C. Gough
Antibodies (2023) Vol. 12, Iss. 1, pp. 7-7
Open Access | Times Cited: 2
Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants
Wenjuan Du, Rick Janssens, Anna Z. Mykytyn, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 2
Yeast-based production platform for potent and stable heavy chain-only antibodies
Chiara Lonigro, Hannah Eeckhaut, Royan Alipour Symakani, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Preclinical animal models to evaluate therapeutic antiviral antibodies
Amse De Meyer, Philip Meuleman
Antiviral Research (2024) Vol. 225, pp. 105843-105843
Closed Access
Design of targeted antiviral polypeptides specific to SARS-CoV-2. Challenges and prospects
О. Н. Шилова, Е. С. Шилов, Sergey M. Deyev
Russian Chemical Reviews (2024) Vol. 93, Iss. 6, pp. RCR5128-RCR5128
Closed Access
Backstage Heroes—Yeast in COVID-19 Research
Wojciech Grabiński, Andonis Karachitos, Anna Kicińska
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 23, pp. 12661-12661
Open Access
Impaired immune response drives age-dependent severity of COVID-19
Julius Beer, Stefania Crotta, Angele Breithaupt, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 2
Arsenal of Nanobodies for Broad-Spectrum Countermeasures against Current and Future SARS-CoV-2 Variants of Concerns
Martín A. Rossotti, Henk van Faassen, Anh Tran, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 2
Broadly neutralizing and protective nanobodies against diverse sarbecoviruses
Mingxi Li, Yifei Ren, Zhen Qin Aw, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1

Scroll to top